NCT07229937

A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of HRS-1301 in Participants With Dyslipidemia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 189 (estimated)
• Sponsor: Shandong Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.

Conditions

• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	HRS-1301	HRS-1301 Dose 1，oral
DRUG	HRS-1301	HRS-1301 Dose 2，oral
DRUG	HRS-1301	HRS-1301 Dose 3，oral
DRUG	HRS-1301	HRS-1301 Dose 4，oral
DRUG	Placebo	Placebo，oral

Timeline

• Start date: 2025-11-25
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2025-11-17
• Last updated: 2025-12-12

Locations

1 site across 1 country: China